clinicopathology figures and survival of non-hodgkin’s lymphoma in iran

Background: non-hodgkin’s lymphoma (nhl) is the fifth most frequently diagnosed cancer whose incidence has risen by at least 100 percent over the past five decades especially in thewest. objectives: the aim of this study is to investigate clinicopathology figures, overall survival (os) and progression-free survival (pfs) in patients with nhl in iran. methods: in a descriptive study, 143 patients referred to clinic of hematology in two centers between 2005 and 2014. we checked age, sex, types and subtypes of nhl; recurrence, ki-67, organomegaly, lymphadenopathy, radiotherapy, os and pfs in the patients. the mean follow-up was 49 months. all patients received r-chop regimen for 6 to 8 cycles. results: the mean age at diagnosis for the patients was 46 years (range, 16 - 82) and 76.9% had age < 60 years and 62.2% were male. 58% patients had primary nodalnhlandout of 139 patients, 88.5% were aggressive nhl. organomegaly and lymphadenopathy were in 12 patients (8.4%) and 80 (55.9%), respectively. of all patients, 106 patients (74.1%) were treated with radiotherapy. 2-year os rate was 91.5% and 5-year os rate was 85%.2-and 5-year pfs rates were 79.6% and 63.3%, respectively. conclusions: percentage of nhl in males is more than females and the median age is around 45 years. also, the prevalence of nodal is more compared with extranodal in nhl patients.